Innate Pharma SA Retained Earnings Profit Loss For Reporting Period
Innate Pharma SA (IPHA) had Retained Earnings Profit Loss For Reporting Period of -EUR 49.18 million as of 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Notes
ifrs-full:RetainedEarningsProfitLossForReportingPeriod · last filed 2026-04-01
- 2025-12-31: Retained Earnings Profit Loss For Reporting Period -49.18M EUR.
- 2025-06-30: Retained Earnings Profit Loss For Reporting Period -21.34M EUR.
- 2024-12-31: Retained Earnings Profit Loss For Reporting Period -49.47M EUR.
- 2024-06-30: Retained Earnings Profit Loss For Reporting Period -24.76M EUR.
| Period end | Retained Earnings Profit Loss For Reporting Period |
|---|---|
| 2025-12-31 | -49.18M EUR 20-F · filed 2026-04-01 |
| 2025-06-30 | -21.34M EUR 6-K · filed 2025-09-17 |
| 2024-12-31 | -49.47M EUR 20-F · filed 2026-04-01 |
| 2024-06-30 | -24.76M EUR 6-K · filed 2024-09-12 |
| 2023-12-31 | -7.57M EUR 20-F · filed 2026-04-01 |
| 2023-06-30 | 1.72M EUR 6-K · filed 2023-09-14 |
| 2022-12-31 | -58.10M EUR 6-K · filed 2023-09-14 |
| 2022-06-30 | 6.30M EUR 6-K · filed 2022-09-15 |
| 2021-12-31 | -52.81M EUR 6-K · filed 2022-09-15 |